Mustang Bio, Inc.
MBIONASDAQHealthcare● Active
$0.70
+$0.03(+4.49%)
Market Cap$5305011
P/E Ratio—
52W High$7
52W Low$0.531
Mustang Bio, Inc. (MBIO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MBIO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.14
Est. -$140.00 · +99.9%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
MBIO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | -$145.50 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 5, 2026 | -$140.00 | -$0.14 | +99.9% | — | — | — |
| ▲ Q1 FY2026 | Mar 19, 2026 | -$5.50 | -$0.08 | +98.5% | — | — | — |
| — Q4 FY2025 | Nov 7, 2025 | — | -$0.07 | — | — | — | — |
| — Q3 FY2025 | Aug 8, 2025 | — | -$0.19 | — | — | — | — |
| — Q2 FY2025 | May 14, 2025 | — | -$0.05 | — | — | — | — |
| ▼ Q1 FY2025 | Mar 24, 2025 | -$5.50 | -$37.95 | -590.0% | — | — | — |
| ▲ Q4 FY2024 | Nov 8, 2024 | -$6.50 | -$2.00 | +69.2% | — | — | — |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
-$145.50
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
-$0.14
EPS Est.
-$140.00
EPS Surpr.
+99.9%
Revenue
—
Q1 FY2026
Mar 19, 2026Beat
EPS Actual
-$0.08
EPS Est.
-$5.50
EPS Surpr.
+98.5%
Revenue
—
Q4 FY2025
Nov 7, 2025
EPS Actual
-$0.07
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 8, 2025
EPS Actual
-$0.19
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 14, 2025
EPS Actual
-$0.05
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 24, 2025Miss
EPS Actual
-$37.95
EPS Est.
-$5.50
EPS Surpr.
-590.0%
Revenue
—
Q4 FY2024
Nov 8, 2024Beat
EPS Actual
-$2.00
EPS Est.
-$6.50
EPS Surpr.
+69.2%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2030 | $-5.50 | $-5.50 | $-5.50 | 1 |
| Q4 FY2029 | $-6.50 | $-6.50 | $-6.50 | 1 |
| Q3 FY2029 | $-7.00 | $-7.00 | $-7.00 | 1 |
| Q2 FY2029 | $-43.50 | $-43.50 | $-43.50 | 1 |
| Q1 FY2029 | $-77.83 | $-77.83 | $-77.83 | 1 |
| Q4 FY2028 | $-63.75 | $-63.75 | $-63.75 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2030 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +99.9% | $0.75 | $0.77 | +2.93% |
| ▲ Q1 FY2026 | Mar 19, 2026 | +98.5% | $0.86 | $0.85 | -1.13% |
| — Q4 FY2025 | Nov 7, 2025 | — | $1.26 | $1.22 | -3.17% |
| — Q3 FY2025 | Aug 8, 2025 | — | $1.52 | $1.66 | +9.21% |
| — Q2 FY2025 | May 14, 2025 | — | $1.12 | $1.12 | +0.00% |
| ▼ Q1 FY2025 | Mar 24, 2025 | -590.0% | $1.40 | $1.41 | +0.71% |
| ▲ Q4 FY2024 | Nov 8, 2024 | +69.2% | $12.40 | $12.75 | +2.82% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -71.4% | $17.35 | $17.77 | +2.42% |
Q2 FY2026+2.93%
Report Date
May 5, 2026
EPS Beat/Miss
+99.9%
Price Before
$0.75
Price After
$0.77
Q1 FY2026-1.13%
Report Date
Mar 19, 2026
EPS Beat/Miss
+98.5%
Price Before
$0.86
Price After
$0.85
Q4 FY2025-3.17%
Report Date
Nov 7, 2025
EPS Beat/Miss
—
Price Before
$1.26
Price After
$1.22
Q3 FY2025+9.21%
Report Date
Aug 8, 2025
EPS Beat/Miss
—
Price Before
$1.52
Price After
$1.66
Q2 FY2025+0.00%
Report Date
May 14, 2025
EPS Beat/Miss
—
Price Before
$1.12
Price After
$1.12
Q1 FY2025+0.71%
Report Date
Mar 24, 2025
EPS Beat/Miss
-590.0%
Price Before
$1.40
Price After
$1.41
Q4 FY2024+2.82%
Report Date
Nov 8, 2024
EPS Beat/Miss
+69.2%
Price Before
$12.40
Price After
$12.75
Q3 FY2024+2.42%
Report Date
Aug 13, 2024
EPS Beat/Miss
-71.4%
Price Before
$17.35
Price After
$17.77
Avg Beat Reaction+1.54%
Avg Miss Reaction+1.56%
Beat Rate3 / 8 quarters
Largest Move+9.21% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MBIO ends December
Mustang Bio, Inc. (MBIO) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.14 — beating the analyst consensus of $-140.00 by +99.9%. MBIO has beaten EPS estimates for 2 consecutive quarters. The next MBIO earnings date is expected around September 1, 2026.
Each quarter, investors track MBIO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MBIO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MBIO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MBIO earnings · 5 questionsMustang Bio, Inc.'s next earnings report is expected around September 1, 2026. MBIO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MBIO historically reports after market close (AMC).
MBIO earnings datewhen is MBIO earningsMBIO next earnings datewhen does MBIO report earningsMBIO earnings calendar
▸ Source: FMP · Mustang Bio, Inc. SEC filings · US GAAP · Mustang Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026